Business Information
The company's principal activity is to develop ophthalmic pharmaceutical products. The research and development of the company is based on proprietary eye drop-based drug delivery technology. The company has retinal programs, which include a therapeutic agent and a retinal drug delivery technology. The drug delivery technology of the company can be customized to deliver a wide variety of potential drug candidates. The company has also developed a diagnostic/prognostic technology isv-900 that is capable of identifying multiple glaucoma genetic markers from a single sample. The products of the company include ocugene, isv-900, isv-205, isv-401, isv-403, isv-205, aquasite and isv-014. The company operates in the United States and the United Kingdom.
|
|
Name |
Title
|
Email
|
| Kumar Chandrasekaran | Chmn., Ceo, Pres. | Available | | Louis Drapeau | CFO, VP | N/A | | David Heniges | VP, GM - Commercial Opportunities | Available | | Lyle Bowman | VP - Development, Operations | N/A | | Ronald Carlson | VP - Regulatory, Quality | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 2 | (16,611) | | 2005 | 4 | (15,215) | | 2004 | 542 | (5,514)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
